Table 7 Interobserver agreement for HCC features in positive and negative hepatic steatosis patients
Non-fatty liver | Fatty liver | |||
|---|---|---|---|---|
IOA percent (%) | Kappa | IOA percent (%) | Kappa | |
APHE (early) | 100 | 1 | 100 | 1 |
APHE (late) | 100 | 1 | 100 | 1 |
Non-peripheral “washout” (portal) | 97.9 | 0.957 | 95.6 | 0.908 |
Non-peripheral “washout” (delayed) | 97.9 | 0.957 | 95.6 | 0.910 |
Enhancing capsule | 93.6 | 0.827 | 93.3 | 0.862 |
Size (50 mm) | 100 | 1 | 100 | 1 |
Threshold growth | 95.7 | 0.832 | 97.8 | 0.942 |
Corona enhancement | 95.7 | 0.810 | 88.9 | 0.483 |
Subthreshold growth | 100 | 1 | 100 | 1 |
Mild–moderate T2 hyperintensity | 100 | 1 | 97.7 | 0.944 |
Restricted diffusion | 95.7 | 0.873 | 93.3 | 1 |
Fat sparing in solid mass | … | 100 | 1 | |
Non-enhancing “capsule”- | … | 97.8 | 0.920 | |
Nodule-in-nodule architecture | 100 | 1 | 100 | 1 |
Mosaic architecture | 97.9 | 0.911 | 97.8 | 0.845 |
Fat in mass, more than adjacent liver | 97.9 | 0.957 | 97.8 | 0.920 |
Blood products in mass | 95.7 | 0.810 | 95.6 | 0.483 |